🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:

Recruitingn/aAges any - anyAllXiangya Hospital of Central South University
NCT07608003 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A vision-language model using preoperative MRI and clinical variables has been developed to simultaneously predict three key molecular markers in midline gliomas: H3K27M, IDH, and 1p/19q. This prospective multicenter study will validate the model's accuracy in preoperative molecular subtyping and its value in prognostic assessment and clinical decision-making across multiple neurosurgical centers.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with diffuse gliomas were pathologically and molecularly diagnosed. * The clinical case data of all patients were complete. * Patients underwent preoperative MRI examination. Exclusion Criteria: * The tumor is not located in the intracranial midline. * Cases in which MRI were incomplete or with significant noise and artifacts.
💊

What it tests

  • Not listed
📍

Where

1 site
Xiangya Hospital of Central South University
Changsha, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy